U. S. SECURITIES AND
Washington, D.C. 20549
x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2001
o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____ to ____
Commission file number 001-13543
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of||(I.R.S. Employer|
|incorporation or organization)||Identification No.)|
Grove Parkway, Saint Paul, Minnesota
(Address of principal executive offices)
Registrants telephone number, including area code: (651) 484-4874
Indicate by check mark whether the issuer
(1) filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes x No o
As of May 10, 2001, the Company had outstanding 3,481,584 shares of common stock, $.01 par value.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
|ANGEION CORPORATION AND SUBSIDIARIES|
|Consolidated Balance Sheets|
|(unaudited, in thousands except share data)|
|Cash and cash equivalents||$6,055||$6,350|
|Accounts receivable, net of allowance for doubtful accounts of $179 and $153, respectively||4,161||4,631|
|Prepaid expenses and other current assets||207
|Total current assets||14,647||15,178|
|Net non-current assets of discontinued operations||212||236|
|Equipment and fixtures, net||1,772||1,895|
|Intangible assets, net||11,824||12,000|
|Liabilities and Shareholders' Equity|
|Net current liabilities of discontinued operations||384||457|
|Other liabilities and accrued expenses||896
|Total current liabilities||3,846||3,515|
|Common stock, $.01 par value. Authorized 10,000,000 shares; issued and outstanding 3,481,584 shares in 2001 and 2000||35||35|
|Additional paid-in capital||123,905||123,905|
|Cumulative translation adjustment||(9)||(9)|
|Total shareholders' equity||5,521
See accompanying notes to financial statements
|ANGEION CORPORATION AND SUBSIDIARIES|
|Consolidated Statements of Operations|
|(unaudited, in thousands except per share amounts)|
|Three Months Ended
|Equipment and supply sales||$3,419||$4,210|
|Cost of goods sold|
|Cost of equipment and supplies||2,255||2,909|
|Cost of service revenue||129
|Selling and marketing||1,150||1,159|
|General and administrative||650||705|
|Research and development||420||376|
|Amortization of intangibles||324
|Other income (expense):|
|Loss before taxes||(1,294)||(1,145)|
|Provision for taxes||-
|Loss from continuing operations||(1,294)||(1,145)|
|Income (loss) from discontinued operations, net of taxes||(29)
|Net income (loss)||$(1,323)
|Net income (loss) per share - basic and diluted|
|Net income (loss)||(0.38)
|Weighted average common shares outstanding|
|Basic and diluted||3,482
See accompanying notes to financial statements
|ANGEION CORPORATION AND SUBSIDIARIES|
|Consolidated Statements of Cash Flows|
|(unaudited, in thousands)|
|Three Months Ended
|Cash Flows From Operating Activities:|
|Net income (loss)||$(1,323)||$9,884|
|Adjustments to reconcile net income (loss) to net cash flows used in operating activities, net of operating assets and liabilities acquired:|
|(Income) loss from discontinued operations||29||(11,029)|
|Depreciation and amortization||492||452|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other current assets||143||29|
|Other liabilities and accrued expenses||459
|Net cash used in continuing operations||(30)||(297)|
|Net cash used in discontinued operations||(102)
|Net cash used in operating activities||(132)
|Cash Flows From Investing Activities:|
|Purchase of equipment and fixtures||(45)||(186)|
|Investment in proprietary software||(142)||(153)|
|Acquisition of operating assets||-
|Net cash used in continuing operations||(187)||(807)|
|Net cash provided by discontinued operations||24
|Net cash provided by (used in) in investing activities||(163)
|Cash Flows From Financing Activities:|
|Borrowings under bank line of credit||-||6,927|
|Payments under bank line of credit||-
|Net cash provided by financing activities||-
|Effect of exchange rate on cash and cash equivalents||-
|Net increase (decrease) in cash and cash equivalents||(295)||6,310|
|Cash and cash equivalents at beginning of period||6,350
|Cash and cash equivalents at end of period||$6,055
|Cash paid for interest expense||$-
See accompanying notes to financial statements
NOTES TO CONSOLIDATED FINANCIAL
March 31, 2001
1. Basis of Presentation
The consolidated balance sheet as of March 31, 2001, the consolidated statements of operations and cash flows for the three months ended March 31, 2001 and 2000, and the related information presented in these notes have been prepared by management in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, without audit. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of results have been included. The balance sheet at December 31, 2000 was derived from the audited financial statements as of that date. Operating results for the three month period ended March 31, 2001 are not necessarily indicative of the results that may be expected for the year ended December 31, 2001. For further information, refer to the financial statements and notes thereto included in Angeion Corporations Annual Report on Form 10-K for the fiscal year ended December 31, 2000.
During March 2000, Angeion Corporation discontinued its historical business, the research, development, manufacturing and marketing of implantable cardioverter defibrillators (ICD). Consequently, the accompanying consolidated statements of operations present all activities of the ICD business under discontinued operations accounting rules. Although the last sales of ICD products were made during the second quarter of 2000, the Company continues to pursue the license or transfer of its ICD technology. As a result of the December 21, 1999 acquisition of Medical Graphics Corporation and discontinuance of the ICD business, Medical Graphics now comprises a majority of the Companys total assets and generates all of its sales. Moreover, the Company is now focusing its efforts on the markets served by and business operations of its wholly-owned subsidiary, Medical Graphics Corporation, and the acquisition and development of future businesses that contribute to shareholder value.
Comprehensive income is a measure of all non-owner changes in shareholders equity and includes such items as net income, certain foreign currency translation items, minimum pension liability adjustments and changes in the value of available-for-sale securities. For the three months ended March 31, 2001 and 2000, comprehensive income (loss) for Angeion Corporation was equivalent to net income (loss) as reported.
Certain amounts in Angeions Form 10-Q for the three month period ended March 31, 2000 have been reclassified to conform to the 2001 presentation. These reclassifications had no effect on net income or shareholders equity as previously reported.
3. Net Income (Loss) Per Share
Basic net income per share is calculated by dividing net income (loss) by the weighted-average common shares outstanding during the period. Net income (loss) per share assuming dilution reflects the potential dilution to basic net income per share that could occur upon conversion or exercise of securities, options, or other such items, to common shares using the if-converted and treasury stock methods based upon the weighted-average fair value of the Companys common shares during the period.
4. New Accounting Pronouncements
Statement of Financial Accounting Standards No. 133 (SFAS No. 133), Accounting for Derivative Instruments and Hedging Activities, (as amended by SFAS No. 137 with respect to the effective date and SFAS No. 138 with respect to certain hedging activities) requires all derivatives to be recognized as assets or liabilities on the balance sheet and measured at fair value on a mark-to-market basis. The adoption of SFAS No. 133 in January 2001 did not have a material effect on the Companys financial statements.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Statements included in this Quarterly Report on Form 10-Q that are not historical or current facts are forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. The words believe, expect, will, can, estimate, anticipate, and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially, including the factors set forth in the Section entitled Certain Risk Factors in Part I, Item 1, Business of the Companys Form 10-K for the year ended December 31, 2000 as well as others not now anticipated. Various forward-looking statements have been made in this Quarterly Report on Form 10-Q and may also be made in other Angeion reports filed under the Securities Exchange Act of 1934, in its press releases and in other documents. In addition, from time to time, the Company through its management may make oral forward-looking statements. The Company undertakes no obligation to update any forward-looking statement.
Results of Operations
Angeion Corporation recorded a net loss of $1,323,000 for the three months ended March 31, 2001 compared to net income of $9,884,000 for the same period in 2000. These amounts included losses from continuing operations of $1,294,000 and $1,145,000 for the three months ended March 31, 2001 and 2000, respectively. Discontinued operations reported a loss of $29,000 for 2001 compared to income of $11,029,000 for 2000. Income from discontinued operations for the three months ended March 31, 2000 included a gain of $11,696,000, net of taxes, from the non-exclusive licensing of patent rights and sale of certain assets, offset by $667,000 of discontinued operating expenses.
Revenues consist of product sales and service revenues. Product sales reflect sales of Medical Graphics non-invasive cardio-respiratory diagnostic systems and related software and aftermarket sales of peripherals and supplies. Service revenues reflect contract revenues from extended warranties, non-warranty service visits and training.
Total revenue decreased 17.2% to $4,061,000 from $4,906,000 for the three months ended March 31, 2001 and 2000, respectively. The decrease was primarily due to domestic product revenue which decreased by 21.6% to $2,473,000 in 2001 compared to $3,153,000 in 2000. International revenue decreased by 10.5% to $946,000 in 2001 compared to $1,057,000 in 2000. Service revenue decreased by 7.8% to $642,000 in 2001 from $696,000 in 2000.
Domestic revenue decreased due to 1999 software upgrade orders associated with year 2000 compliance and 1999 system orders that were shipped in the first quarter of 2000 as well as the loss of $583,000 in sales from sleep diagnostics products. The Company discontinued selling sleep diagnostic products in the second quarter of 2000 in order to focus on other products with larger market sizes and profit potential. The domestic order rate for systems increased by 31.5% when comparing the first three months of 2001 to 2000.
International revenue decreased due to 1999 orders for system sales that were shipped in the first quarter of 2000. The international order rate for systems increased by 11.6% when comparing the first three months of 2001 to 2000. The service revenue decrease reflects the carryover of non-warranty service calls from 1999 to 2000 due to the heavy demand and limited resources associated with installation of year 2000 upgrades late in 1999.
The Company anticipates that domestic product orders will continue to increase over the 2000 level. As a result, the Company expects that revenue in the second quarter of 2001 will show an increase compared to second quarter 2000 revenue and a sequential increase over first quarter 2001 revenue.
Gross margin percentage increased to 41.3% of revenue for the three months ended March 31, 2001 compared to 38.2% for the same period of 2000. The margin increase reflects the impact of cost reduction programs, higher sales of higher margin cardiopulmonary exercise testing systems and discontinuance of lower margin sleep diagnostics products, partially offset by lower sales of high margin software upgrade products associated with year 2000 compliance.
Selling and Marketing
Selling and marketing expenses decreased 0.8% to $1,150,000 for the three months ended March 31, 2001 from $1,159,000 in 2000. Increased expenses associated with the Companys focus on the cardiac rehabilitation and disease prevention markets along with additional costs in support of the focus on international revenue were more than offset by lower commissions due to lower sales and generally lower domestic selling expenses.
General and Administrative
General and administrative expenses decreased by 7.8% to $650,000 for the three months ended March 31, 2001 from $705,000 in 2000. Lower personnel costs and shareholder communications expenses were partially offset by higher legal expenses associated with on-going litigation.
Research and Development
Research and development expenses increased by 11.7% to $420,000 from $376,000 for the three months ended March 31, 2001 and 2000, respectively. The first quarter of 2001 includes additional expenses associated with the AeroSport products that were acquired in March 2000. One of those products is instrumental in the Companys current growth initiative for the cardiac rehabilitation and disease prevention markets. The current quarter also reflects the Companys continuing effort to transition its software products to a Windows 98/NT/2000 platform.
Amortization of Intangibles
Amortization of intangibles represents the amortization of goodwill and other intangible assets associated with acquisitions. Amortization expenses increased by 13.7% to $324,000 from $285,000 for the three months ended March 31, 2001 and 2000, respectively. The increase reflects the acquisition of AeroSports technology in March 2000 and the capitalization of eligible costs associated with on-going enhancement of the Companys proprietary software products.
Other Income (Expense)
Interest income increased to $83,000 for the three months ended March 31, 2001 compared to $80,000 for 2000. The increase reflects higher excess cash balances available for short term investment partially offset by lower interest rates.
Interest expense for the three months ended March 31 decreased to $510,000 in 2001 compared to $574,000 in 2000. The decrease represents the minimum interest charges incurred during the first quarter of 2000 for the Medical Graphics bank line of credit that expired by its terms on March 31, 2000.
Income From Discontinued Operations
The loss from discontinued operations of $29,000 for the three months ended March 31, 2001 represents expenses related to discontinued operations.
Income from discontinued operations of $11,029,000 for the three months ended March 31, 2000, includes a one-time gain of $11,696,000, net of taxes, related to the non-exclusive licensing of patent rights and sale of certain assets. The gain was partially offset by $593,000 of rental expenses associated with the building previously used for ICD products as well as other expenses of $74,000 related to discontinued operations.
Liquidity and Capital Resources
The Company had cash of $6,055,000 and working capital of $10,801,000 as of March 31, 2001. During the three months ended March 31, 2001, the Company used $30,000 in cash for continuing operations. Cash was provided by a $470,000 decrease in accounts receivable and an increase of $459,000 in other liabilities and accrued expenses, which were offset by a $245,000 increase in inventory and a $142,000 decrease in accounts payable. In addition, the Company used $102,000 in cash for discontinued operations which included $73,000 for rental of the facility formerly used for the Companys ICD products.
During the three months ended March 31, 2001, the Company used $163,000 in cash for investing activities. Cash was used to increase the Companys investment in proprietary software by $142,000 and to purchase $45,000 of equipment and fixtures. Cash of $24,000 was generated from the sale of assets related to discontinued operations.
At March 31, 2001 the Company had no material commitments for capital expenditures. The Company believes that its cash flows from operations together with its existing cash will be adequate to satisfy its liquidity and capital resource needs through March 2002.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The Company invests its cash in money market instruments or short-term investment grade securities. The Company believes that a decrease of 100 basis points in prevailing interest rates would not have an adverse effect on its net income or financial position.
The Companys product sales outside the United States are denominated in United States dollars. Accordingly, the Company believes its exposure to foreign exchange rate fluctuation is minimal.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
Note Holder Litigation
On September 24, 1999, U.S. Bank National Association, as Trustee on behalf of holders of Angeion 7½% Senior Convertible Notes due April, 2003 brought suit against the Company in Hennepin County District Court in the State of Minnesota. The lawsuit sought injunctive relief, a declaratory judgment, and breach of contract and related relief, alleging that certain actions taken by Angeion in 1998 and 1999 constituted a sale of all or substantially all of Angeions assets, and thereby constituted a Designated Event under terms of the Indenture governing the Notes, thereby requiring repayment of the Notes.
On November 30, 1999, the District Court denied the Trustees request for a temporary injunction in this matter. On February 7, 2000, the District Court dismissed the suit against Angeion, ruling that these transactions did not constitute the sale of all or substantially all of the assets of Angeion, that no Designated Event had occurred, and that the Note holders were not entitled to prepayment of their Notes. The Trustee appealed both Orders to the Minnesota Court of Appeals.
On August 15, 2000, the Minnesota Court of Appeals upheld the decision of the District Court denying injunctive relief, but ruled that the District Court determination that the transaction did not constitute a sale of all or substantially all of the assets of Angeion was premature and reversed and remanded the case for further discovery on that issue. The Court of Appeals also stated that the sale or license of patent rights could constitute a sale of all or substantially all of the assets of a corporation. The Court of Appeals also determined, however, that the January 1999 Restructuring, the April 1999 Restructuring and the Withdrawal Agreement did not convey, transfer, or lease assets and that therefore, as a matter of law these actions could not trigger an obligation to make a repurchase offer.
On September 14, 2000, Angeion petitioned the Minnesota Supreme Court for review of the decision of the Court of Appeals. In an order dated October 25, 2000, Angeions petition for further review was denied. Accordingly, the case has been returned to the District Court for further discovery. Discovery has been conducted since that date.
On March 23, 2001, the District Court issued a scheduling order that, among other things, requires the parties to complete discovery by August 1, 2001 and to complete mediation by September 1, 2001.
Other Legal Matters
The Company is also subject to certain claims and lawsuits that have been filed in the ordinary course of business. It is managements opinion that the settlement of all litigation arising in the ordinary course of business would not have a material effect on the financial position of the Company.
Item 2. Changes in Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Submission of Matters to a Vote of Security Holders
Item 5. Other Information
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits List
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the three months ended March 31, 2001.
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: May 14, 2001||/s/ Richard E. Jahnke
|Richard E. Jahnke, President and Chief|
|(Principal Executive Officer)|
|Date: May 14, 2001||/s/ Dale H. Johnson
|Dale H. Johnson, Chief Financial Officer|
|(Chief Accounting Officer)|
INDEX TO EXHIBITS